Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Melanoma
90%
Health Care Cost
57%
Systematic Review
44%
Sentinel Lymph Node Biopsy
44%
Hazard Ratio
38%
Overall Survival
33%
Progression Free Survival
27%
Melanoma Skin Cancer
25%
Survival Rate
25%
Cost-Effectiveness Analysis
24%
Meta-Analysis
24%
Metastatic Melanoma
22%
Network Meta-Analysis
22%
Cancer Therapy
22%
Long Term Survival
22%
Quality Adjusted Life Year
22%
Head and Neck Cancer
22%
Radiation Therapy
22%
Cost Benefit Analysis
22%
Diagnostic Performance
22%
Neoadjuvant Therapy
22%
Fine-Needle Aspiration
18%
Nivolumab
17%
Quality of Life
17%
Relative Survival
16%
Immune Checkpoint Inhibitor
15%
Ipilimumab
14%
Xerostomia
13%
Plummer-Vinson Syndrome
13%
Systemic Therapy
11%
Adjuvant Therapy
11%
Immunotherapy
10%
Clinical Trial
9%
Sore Throat
8%
Randomized Controlled Trial
8%
Nodal Metastasis
7%
Sensitivity and Specificity
7%
Health Status
6%
Cohort Analysis
6%
Vemurafenib
6%
Dabrafenib
6%
Cancer Registry
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Cutaneous Melanoma
44%
Nivolumab
32%
Progression Free Survival
31%
Overall Survival
25%
Ipilimumab
23%
Randomized Controlled Trial
23%
Survival Rate
22%
Recurrent Disease
22%
Long Term Survival
22%
Immune Checkpoint Inhibitor
15%
Chemotherapy
12%
Binimetinib
11%
Encorafenib
11%
Vemurafenib
9%
Dabrafenib
9%
Clinical Trial
9%
Immunotherapy
9%
Cancer Registry
7%
Disease Exacerbation
7%
Systemic Treatment
7%
Life Expectancy
7%
Cobimetinib
6%
Dacarbazine
6%
Trametinib
6%
Pembrolizumab
6%
Cohort Study
6%
Health Status
5%